Immune checkpoint inhibitors plus anti-angiogenesis in patients with resected high-risk hepatitis B virus-associated hepatocellular carcinoma

Table 2 Comparison of survival outcomes with or without postoperative combined therapy

Duration (months)	Non-PCT, %	PCT, %	P of log-rank	HR (95%CI), P value	Adjusted HR (95%CI), P value
RFS before PSM and IPTW
6	81.7 (75.0, 88.9)	93.3 (84.8, 100.0)	0.119	0.33 (0.08-1.42), 0.138	0.17 (0.04-0.78), 0.022
12	67.9 (60.0, 76.9)	79.3 (65.8, 95.6)	0.183	0.56 (0.24-1.33), 0.188	0.32 (0.12-0.80), 0.015
18	59.8 (51.1, 69.9)	59.8 (42.8, 83.7)	0.590	0.83 (0.42-1.64), 0.590	0.48 (0.22-1.02), 0.055
24	49.7 (40.1, 61.7)	53.2 (35.4, 79.9)	0.567	0.83 (0.43-1.59), 0.567	0.50 (0.24-1.03), 0.061
RFS after PSM
6	79.3 (65.9, 95.5)	96.6 (90.1, 100.0)	0.041	0.15 (0.02-1.24), 0.078
12	72.1 (57.3, 90.6)	82.0 (68.9, 97.7)	0.322	0.57 (0.19-1.75), 0.328
18	62.7 (46.5, 84.6)	61.9 (44.6, 86.0)	0.855	0.92 (0.37-2.27), 0.855
24	55.8 (38.2, 81.4)	55.0 (36.8, 82.2)	0.908	0.95 (0.40-2.25), 0.908
RFS after IPTW
6	81.4 (74.5, 88.8)	92.1 (80.5, 100.0)	0.095	0.38 (0.07-1.96), 0.249
12	67.3 (59.2, 76.6)	78.6 (63.6, 97.3)	0.161	0.57 (0.23-1.44), 0.236
18	59.6 (50.8, 69.9)	65.0 (47.7, 88.5)	0.375	0.73 (0.34-1.55), 0.411
24	49.3 (39.5, 61.5)	56.9 (38.0, 85.3)	0.386	0.75 (0.37-1.51), 0.418
OS before PSM and IPTW
6	95.0 (91.2, 99.0)	100.0 (100.0, 100.0)	0.216	0.00 (0.00-Inf), 0.998	0.00 (0.00-Inf), 0.999
12	88.8 (83.2, 94.7)	96.7 (90.5, 100.0)	0.224	0.30 (0.04-2.33), 0.252	0.21 (0.03-1.71), 0.143
18	85.7 (79.4, 92.5)	96.7 (90.5, 100.0)	0.149	0.25 (0.03-1.90), 0.182	0.19 (0.02-1.49), 0.113
24	82.5 (75.2, 90.5)	89.2 (75.2, 100.0)	0.280	0.46 (0.11-1.97), 0.292	0.30 (0.06-1.41), 0.127
OS after PSM
6	93.1 (84.3, 100.0)	100.0 (100.0, 100.0)	0.154	0.00 (0.00-Inf), 0.999
12	89.7 (79.2, 100.0)	96.6 (90.1, 100.0)	0.300	0.32 (0.03-3.09), 0.326
18	89.7 (79.2, 100.0)	96.6 (90.1, 100.0)	0.300	0.32 (0.03-3.09), 0.326
24	83.3 (68.8, 100.0)	89.1 (75.1, 100.0)	0.463	0.53 (0.10-2.93), 0.470
OS after IPTW
6	95.1 (91.3, 99.0)	100.0 (100.0, 100.0)	0.016	0.00 (0.00-0.00), P < 0.001
12	88.3 (82.4, 94.6)	96.7 (90.5, 100.0)	0.083	0.29 (0.04-2.22), 0.233
18	85.4 (78.9, 92.5)	96.7 (90.5, 100.0)	0.036	0.25 (0.03-1.85), 0.174
24	82.4 (75.0, 90.5)	90.0 (76.8, 100.0)	0.133	0.41 (0.09-1.81), 0.242

Data are presented as rate (95% confidence interval) or hazard ratio (95% confidence interval). PCT: Postoperative combined therapy; CI: Confidence interval; HR: Hazard ratio; RFS: Recurrence-free survival; PSM: Propensity score matching; IPTW: Inverse probability of treatment weighting; OS: Overall survival.